Home » INNOVIVE COMPLETES $2.25 MILLION PRIVATE FINANCING
INNOVIVE COMPLETES $2.25 MILLION PRIVATE FINANCING
Innovive Pharmaceuticals, a biopharmaceutical company headquartered in Manhattan, has announced that it has raised $2.25 million in a convertible note financing. Paramount BioCapital served as the placement agent. "This is a vote of investor confidence in Innovive's progress and plans," said Steven Kelly, Innovive's president and chief executive officer. Innovive recently licensed worldwide rights for the use of INNO-105 in oncology from Penn State University.
Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050629005243&newsLang=en)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
07May
-
14May
-
30May